|HEPATITIS B IMMUNE GLOBULIN
HepaGam B, HyperHep, Nabi-HB
Classifications: vaccine; Therapeutic: vaccine
Prototype: Hepatitis B vaccine
Pregnancy Category: C
1 mL, 4 mL, 5 mL vials
Sterile solution of immunoglobulins [immunoglobulin G (IgG)] prepared by a special process using pooled human plasma. The
possibility of transmission of hepatitis infection or AIDS from H-BIG is remote.
Preparation contains a high antibody titer specific to hepatitis B surface antigen (anti-HBs); plasma does not show serologic
evidence of hepatitis B surface antigen (HBsAg).
Prophylactically to provide passive immunity to hepatitis B infection in individuals exposed to HBV or HBsAg-positive materials
(blood plasma, serum). Also as postexposure prophylaxis after bite or percutaneous exposure, ingestion, direct mucous membrane
contact, sexual or intimate contact, and in neonates born to HBsAg-positive women. Prevention of hepatitis B reccurrence
following liver transplant (HepaGam B only).
Pregnancy (category C).
History of systemic allergic reactions to immune globulin, concurrent administration of immunosuppression drugs; thrombocytopenia
or bleeding disorders, HBsAg-positive individuals, patients with specific immunoglobulin A (IgA) deficiency; lactation.
Route & Dosage
|Hepatitis B Prophylaxis
Adult/Child: IM 0.06 mL/kg as soon as possible after exposure, preferably within 24 h, but no later than 7 d, repeat 2830 d after
Child: IM 0.5 mL as soon as possible after birth, but no later than 24 h, repeat dose 3 and 6 mo later
Prevention of Recurrence Post-Liver Transplant (HepaGram B)
Adult: IV 20,000 U/dose daily (days 17), every 2 wk (week 212), monthly thereafter
- Give hepatitis B immune globulin at the same time or up to 1 mo preceding hepatitis B vaccination (hepatitis B vaccine)
does not impair the active immune response from the vaccination.
- Give preferably into deltoid muscle or anterolateral aspect of thigh.
- Note: For neonates and small children the preferred injection site is the anterolateral aspect of the thigh.
- DO NOT administer by IV; inadvertent IV or intravascular administration can cause a precipitous fall in BP and an
- Store at 2°8° C (36°46° F) unless otherwise directed. Avoid freezing.
Adverse Effects (≥1%)Body as a Whole:
Muscle stiffness; pain, tenderness, swelling, erythema
of injection site, nausea, faintness, fever, dizziness, malaise
lassitude, body and joint pain, leg cramps. Skin:
Urticaria, rash, angioedema, pruritus, erythema
, sensitization (following large or repeated doses), anaphylaxis (rare).
May interfere with immune response
to live-virus vaccines
Slowly absorbed from IM site. Onset:
16 d. Peak:
311 d. Duration:
26 mo. Elimination: Half-life
Assessment & Drug Effects
- Have epinephrine 1:1000 readily available; hypersensitivity reactions are most likely to occur in patients receiving large
doses or repeated injections.
Patient & Family Education
- Learn potential adverse reactions.